News | September 10, 2008

Good Samaritan Health System Among First to Implant Advanced Defibrillator

September 11, 2008 - Good Samaritan Hospital was among the first in the nation to implant a TELIGEN implantable cardioverter defibrillator (ICD) made by Boston Scientific.

This advanced device is used to treat sudden cardiac death, which is the abrupt loss of heart function, usually due to an electrical rhythm dysfunction in the lower chambers of the heart that causes the heart to pump blood ineffectively.

GSH is among the first to bring this new technology to Central Pennsylvania. Dr. Jeffrey L. Williams, M.D., MS, FACC, implanted the devices in two patients on Aug. 7. This device represents an entirely new platform to treat sudden cardiac death and provides physicians enhanced clinical options for their patients. It is one of the smallest, thinnest implantable defibrillators in the world, featuring innovative new technologies with exceptional longevity.

“Our goal is provide the most state-of-the-art heart rhythm services with a patient- and family-centered care giving approach. We are proud to offer these services to our patients at Good Samaritan Hospital,” said Dr. Williams.

Good Samaritan Hospital’s Cardiac Catheterization Laboratories had an impressive overall Press-Ganey patient satisfaction score of 93.4 percent (from January through March 2008). In addition, Good Samaritan Hospital was awarded an American Heart Association Get With the Guidelines Heart Failure (GWTG–HF) Silver Performance Achievement Award. The award signifies that the hospital reached an aggressive goal of treating heart failure patients based on core standard levels of care as outlined by the AHA/American College of Cardiology.

For more information: www.lebanoncardiology.com, www.gshleb.org

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init